{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:34:09Z","timestamp":1778571249848,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:p><jats:bold>Background\u2002<\/jats:bold> The cobas<jats:sup>\u00ae<\/jats:sup> TaqScreen MPX Test, version 2.0, a multiplex, multi\u2010dye nucleic acid amplification technology (NAT) test from Roche was evaluated by two European Blood Banks, the German Red Cross Blood Donor Service, Frankfurt, Germany and Centro de Hemoterapia y Hemodonaci\u00f3n de Castilla y Le\u00f3n, Valladolid, Spain. In addition, the cobas<jats:sup>\u00ae<\/jats:sup> TaqScreen DPX Test was evaluated for the simultaneous detection and quantitation of parvovirus B19 and the detection of hepatitis A virus (HAV).<\/jats:p><jats:p><jats:bold>Study Design and Methods\u2002<\/jats:bold> The performances of the two tests were evaluated regarding the analytical sensitivity, the reproducibility of the tests using samples containing low concentrations of each virus and cross\u2010contamination using samples containing high titres of virus.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The analytical sensitivity of the MPX Test, version 2.0, obtained by the German Red Cross Blood Donor Service was 1\u00b71, 3\u00b79 and 43\u00b73\u2003IU\/ml for HBV, HCV and HIV\u20101, respectively. The comparable analytical sensitivity at Centro de Hemoterapia y Hemodonaci\u00f3n de Castilla y Le\u00f3n was 3\u00b75, 17\u00b76 and 50\u00b76\u2003IU\/ml for HBV, HCV and HIV\u20101, respectively. The analytical sensitivity of the DPX test determined by the German Red Cross Blood Donor Service was 0\u00b76 and 3\u00b78\u2003IU\/ml for HAV and B19.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> These multiplex and multi\u2010dye blood screening assays represent a flexible NAT screening system for mini\u2010pools between 6 and 96 samples per pool and fulfil all requirements of the European Pharmacopoeia for HCV and B19V testing of plasma for fractionation. The inclusion of a new multi\u2010dye technology means discriminatory assays are no longer required for either test thus improving workflow, turn\u2010around time and minimize the risk of obtaining a reactive result for which the virus cannot be identified.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2012.01635.x","type":"journal-article","created":{"date-parts":[[2012,8,3]],"date-time":"2012-08-03T02:12:43Z","timestamp":1343959963000},"page":"19-29","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of two, commercial, multi\u2010dye, nucleic acid amplification technology tests, for HBV\/HCV\/HIV\u20101\/HIV\u20102 and B19V\/HAV, for screening blood and plasma for further manufacture"],"prefix":"10.1111","volume":"104","author":[{"given":"M. M.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. I. G.","family":"Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Hourfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. B.","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sireis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. T.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Seifried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Saldanha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01506.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01852.x"},{"key":"e_1_2_8_4_2","volume-title":"Human anti\u2010D Immunoglobulin, Monograph 0557 (Since 1\/1\/2004); Human Anti\u2010D Immunoglobulin for Intravenous Administration, Monograph 1527 (Since 1\/1\/2004); Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646 (Since 1\/7\/2004)","author":"Anonymous","year":"2011"},{"key":"e_1_2_8_5_2","unstructured":"Guidance for Industry:Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma\u2010derived Products U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. July 2009http:\/\/www.fda.gov\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_2_8_6_2","volume-title":"Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646 (since 01\/2011)","author":"Anonymous","year":"2011"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21413"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.18.9124-9134.2002"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.05.011"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01219.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.11.5273-5276.2003"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01443.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02780.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04372.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00132.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00633.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00129.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.2002.00383.x"},{"key":"e_1_2_8_19_2","first-page":"23","article-title":"Status of NAT screening for HCV, HIV and HBV \u2013 experiences of the German Red Cross Blood Donation Services","volume":"108","author":"Seifried E","year":"2002","journal-title":"Dev Biol (Basel)"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)06318-1"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00649.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.048603"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00154.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2008.00331.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02343.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00863.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01672.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.06.007"},{"key":"e_1_2_8_29_2","volume-title":"TaqScreen MPX Test, Version 2.0 for Use on the cobas s 201 System","author":"cobas\u00ae","year":"2011"},{"key":"e_1_2_8_30_2","volume-title":"TaqScreen MPX Test, for Use on the cobas s 201 System","author":"cobas\u00ae","year":"2010"},{"issue":"2","key":"e_1_2_8_31_2","first-page":"6","article-title":"Zelos x100 enables detection of transfusion relevant viruses as well as bacterial detection in platelets \u2013 a new cost efficient alternative to commercial bacterial screening methods","volume":"101","author":"Seifried E","year":"2011","journal-title":"Vox Sang"},{"key":"e_1_2_8_32_2","volume-title":"Procleix Ultrio Assay, 500939 Rev. A","author":"Gen\u2010Probe, Incorporated","year":"2008"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01966.x"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01965.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01343.x"},{"key":"e_1_2_8_36_2","volume-title":"TaqScreen DPX Test for Use on the cobas s 201 System","author":"IFU cobas\u00ae","year":"2010"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03705.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2012.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2012.01635.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T20:39:23Z","timestamp":1698525563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2012.01635.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1423-0410.2012.01635.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2012.01635.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}